STOCK OPTION AGREEMENT CYPLASIN BIOMEDICAL LTD.Stock Option Agreement • July 3rd, 2007 • Cyplasin Biomedical Ltd. • Pharmaceutical preparations
CYPLASIN BIOMEDICAL LTD., a company incorporated pursuant to the laws of the State of Nevada, of Unit 131 Advanced Technology Center, 9650 - 20th Avenue NW, Edmonton, AB Canada
ContractPrivate Placement Subscription Agreement • July 29th, 2005 • Glass Wave Enterprises, Inc. • Services-miscellaneous amusement & recreation • Nevada
THIS PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT (THE "SUBSCRIPTION AGREEMENT") RELATES TO AN OFFERING OF SECURITIES IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED HEREIN) PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT").
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 8th, 2011 • Cyplasin Biomedical Ltd. • Pharmaceutical preparations • California
THIS AGREEMENT dated as of the 19th day of July 2010 (the “Agreement”) between TANGIERS INVESTORS, LP, a Delaware limited partnership (the “Investor”), and CYPLASIN BIOMEDICAL LTD., a corporation organized and existing under the laws of the State of Nevada the “Company”).
MANAGEMENT CONSULTING AGREEMENTManagement Consulting Agreement • May 1st, 2007 • Cyplasin Biomedical Ltd. • Services-miscellaneous amusement & recreation • Alberta
BIOXEN Ltd, a company residing at Nautilus House, La Cour des Casernes, St. Helier, Jersey JE1 3NH Channel Islands, (the “Consultant”)
User Agreement for PayPal™ ServiceUser Agreement • May 25th, 2005 • Glass Wave Enterprises, Inc. • California
This User Agreement applies to all countries in which PayPal is available other than Switzerland, Australia and the countries within the European Union. The User Agreement for- Germany is available under the "DE" link above. The User Agreement for France is available under the "FR" link above. The User Agreement for Belgium is available in both English and French under the "BE (in English)" and "BE (in French)" links above. The User Agreement for all other European Union countries is available under the "EU" link above. The User Agreement for Switzerland is available under the "CH" link above. The User Agreement for Italy is available under the "IT" link above.
ASSET ASSIGNMENT AGREEMENTAsset Assignment Agreement • April 12th, 2011 • Compass Biotechnologies Inc. • Pharmaceutical preparations • Nevada
Dr Joseph Sinkule a resident of Scottsdale, Arizona and C- Virionics Corporation. whose principle address is 42191 N. 111th Place, Scottsdale, Arizona, 85262 (herein collectively the Assignor);
LETTER OF AGREEMENTLetter of Agreement • February 8th, 2011 • Cyplasin Biomedical Ltd. • Pharmaceutical preparations • New York
WHEREAS, Minapharm is engaged in the development and commercial sales of pharmaceutical products within the Arab Republic of Egypt and the MENA region including a version of pegylated interferon-alpha (PEG-IFN) used as a Hepatitis C therapeutic drug,;
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • April 13th, 2007 • Cyplasin Biomedical Ltd. • Services-miscellaneous amusement & recreation • England and Wales
EXCLUSIVE LICENSE and OPTION AGREEMENTExclusive License Agreement • February 8th, 2011 • Cyplasin Biomedical Ltd. • Pharmaceutical preparations • Nevada
This Exclusive License Agreement (the “Agreement”) is entered into as of February 7, 2009 (the “Effective Date”), by and between Bioxen Ltd including its affiliates, legal successors and subsidiaries with its principal offices registered as Nautilus House, La Cour des Casernes, St.Helier.Jersey, JE1 3NH, Channel Islands (“Bioxen”) and Cyplasin Biomedical Ltd., a (Nevada corporation), with its principal offices located at Unit 131 Advanced Technology Center, 9650-20th ave., Edmonton, Alberta Canada T6N1G1 including its affiliates, legal successors and subsidiaries, (“Cyplasin”); and collectively referred to as the “Parties”; and
CONSULTING AGREEMENTConsulting Agreement • September 19th, 2011 • Compass Biotechnologies Inc. • Pharmaceutical preparations • California
This Consulting Agreement (the "Agreement"), effective as of July 5, 2011 is entered into by and between Compass Biotechnologies, Inc., (herein referred to as the "Company"), having its' principal place of business at 9650 20th Ave. NW Suite 131 Edmonton AB T6N I G1 and Paradigm Concepts Inc., (herein referred to as the "Consultant") having its' principal place of business at 2173 Salk Avenue, Suite 250 Carlsbad, CA 92008.
SHARE PURCHASE AGREEMENTShare Purchase Agreement • May 25th, 2005 • Glass Wave Enterprises, Inc. • British Columbia
GLASS WAVE ENTERPRISES, INC. a Nevada Corporation with a registered office at 3155 E. Patrick Lane., Suite 1, Las Vegas, Nevada 89120-3481, U.S.A. (the "Purchaser")
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • February 5th, 2007 • Glass Wave Enterprises, Inc. • Services-miscellaneous amusement & recreation • Alberta
NOW THEREFORE in consideration of the premises and the respective covenants, agreements representations, warranties and indemnities of the parties herein contained and for other good and valuable consideration (the receipt and sufficiency of which is hereby acknowledged) the parties hereto covenant and agree as follows:
03/01/05 607-1295 Richards StreetManaged Hosting Agreement • May 25th, 2005 • Glass Wave Enterprises, Inc.
SubleaseSublease • May 25th, 2005 • Glass Wave Enterprises, Inc.
ContractManaged Hosting Agreement • July 29th, 2005 • Glass Wave Enterprises, Inc. • Services-miscellaneous amusement & recreation
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 8th, 2011 • Cyplasin Biomedical Ltd. • Pharmaceutical preparations • Nevada
This Exclusive License Agreement (the “Agreement”) is entered into as of July 1, 2009 (the “Effective Date”), by and between Virionics Corporation, a Delaware corporation having its principal offices at 42191 N. 111th Place, Scottsdale, Arizona, 85262 (“Virionics”), and Cyplasin Biomedical Inc., with its principal offices located at Unit 131 Advanced Technology Center, 9650-20th Ave., Edmonton, Alberta Canada T6N 1G1 including its legal successors and subsidiaries, (“Cyplasin”); and collectively referred to as the “Parties”; and
